Pall Retains Inactine U.S. Marketing Option Under Altered Terms With Vitex
This article was originally published in The Gray Sheet
Executive Summary
Pall Corp. will decide at the end of one year whether to revert to exclusive U.S. marketing rights for Vitex' Inactine red blood cell pathogen reduction system